Abstract
HSP90 is released by cancer cells in the tumor microenvironment where it associates with different co-chaperones generating complexes with specific functions, ranging from folding and activation of extracellular clients to the stimulation of cell surface receptors. Emerging data indicate that these functions are essential for tumor growth and progression. The understanding of the exact composition of extracellular HSP90 complexes and the molecular mechanisms at the basis of their functions in the tumor microenvironment may represent the first step to design innovative diagnostic tools and new effective therapies. Here we review the impact of extracellular HSP90 complexes on cancer cell signaling and behavior.
Introduction
In order to survive and proliferate in a highly stressful environment cancer cells upregulate chaperone expression and actively release chaperones in the extracellular milieu to guarantee their survival and sustain their aberrant evolution toward malignancy (Velichko et al., 2013).
The Heat Shock Protein 90 (HSP90) is a highly conserved and ubiquitously expressed chaperone essential for cell survival. It represents the 1–2% of the total protein content and plays multiple roles, ranging from protein folding to buffering protein denaturation and assisting protein conformational changes (Schopf et al., 2017). Overexpression of HSP90 promotes cell survival, sustains oncogenic signal transduction, cell proliferation and migration (). High HSP90 levels are frequent in human cancer and correlates with poor prognosis (), with the exception of some specific tumor contexts (Nanbu et al., 1998).
HSP90 comes in two isoforms, the stress-induced HSP90α and the constitutively expressed HSP90β (Sreedhar et al., 2004). In physiological conditions, normal cells express more HSP90β than HSP90α (Ullrich et al., 1989) while in cancer cells HSP90α doubles HSP90β expression level (Zuehlke et al., 2015; ). HSP90α underexpression correlates with favorable outcome in some cancer types (; ).
The Intracellular HSP90 Machinery
HSP90 forms a flexible homodimer and binds to its clients, promoting modifications in their structure in an ATP dependent manner. A single monomer of HSP90 is composed by three domains: an N-terminal ATP-binding domain, a middle domain and a C-terminal dimerization domain. In order to fold client proteins, the HSP90 dimer undergoes conformational rearrangements switching between a closed N-terminal conformation and an open one (Figure 1A). Co-chaperones bind sequentially and reversibly to HSP90 to regulate its conformational changes, its ATPase activity and to confer specificity to clients. Client proteins are bound by the HSP70/HSP40 complex, which is stabilized by HSP70-interacting protein (HIP). The HSP90/HSP70 organizing protein (HOP) facilitates the interaction between HSP90 and HSP70 and the translocation of the client protein to HSP90 (Schopf et al., 2017). The HSP70/HOP complex stabilizes HSP90 in the open conformation and inhibits its ATPase activity. This state primes the binding of peptidyl-prolyl isomerases (PPIases), such as FK506 Binding Proteins (FKBP51 and FKBP52), which support cycle progression. Activator of HSP90 ATPase homolog 1 (AHA1) weakens the interaction between HOP and HSP90, promoting HOP and HSP70 release and the transition toward the N-terminal closed state (closed 1). The binding of p23 displaces AHA1, inducing the switch to a completely closed state (closed 2), which is followed by ATP hydrolysis, the return to the open conformation and the release of the client together with p23 and PPIases (Rohl et al., 2013). Cell division cycle 37 homolog (CDC37) is a crucial HSP90 ATPase-inhibiting co-chaperone which stabilizes the HSP90 open form and recruits kinase clients (Siligardi et al., 2002; Taipale et al., 2012). The protein phosphatase and co-chaperone PP5 associates with HSP90 N-terminal domain and dephosphorylates HSP90 and CDC37, regulating client protein processing (). The ability to interact with HSP90 N-terminal domain is also a property of CHORD (Cysteine and Histidine Rich Domain) containing proteins. Indeed, Morgana and Melusin bind to HSP90 preferentially when it is in an ADP-bound state (), favoring the protection of cells from different stress stimuli (Michowski et al., 2010; ; Sorge and Brancaccio, 2016).
FIGURE 1
Extracellular HSP90
HSP90 emerged as one of the more abundant secreted chaperones in normal cells as keratinocytes, dermal fibroblasts and neurons (Sidera et al., 2004; Sidera and Patsavoudi, 2008; , 2013; ). The lack of a secretory signal peptide and experimental data (Santos et al., 2017; ) indicate that chaperone secretion relies on unconventional mechanisms. HSP90 secretion can be induced by various environmental stimuli. Hypoxia-inducible factor 1 alpha (HIF-1α) stabilization in hypoxic conditions (Li et al., 2007; Sahu et al., 2012) and extracellular signal-regulated kinase (ERK) pathway activation in response to oxidative stress (Liao et al., 2000) are both able to stimulate HSP90 secretion. In the extracellular compartment, HSP90 may exist in a soluble form, but it can be also found bound to phospholipids on plasma membrane and even on the surface or inside exosomes (Shevtsov et al., 2020). eHSP90α promotes cell migration and invasion, crucial processes in tissue morphogenesis, embryonic development, and wound healing processes (Wong and Jay, 2016).
eHSP90 in Cancer Progression
The release of HSP90, mainly HSP90α, from cancer cells and its role in promoting cancer cell survival, migration, invasion, and stemness through autocrine mechanisms is well established (Liu et al., 2019; Secli et al., 2021). Cells of the tumor microenvironment also express HSP90 receptors and several studies reported the binding of HSP90 to their surface (). eHSP90α may mediate fibroblast migration and conversion to cancer associated fibroblasts (; Tang et al., 2019) as well as migration and tubulogenesis in lymphatic endothelial cells (). By interacting with immune cells in the tumor microenvironment, HSP90 may also exert anti-tumoral functions. Indeed, HSP90 is released from cancer cells bound to oncopeptides and facilitates their presentation to antigen presenting cells, stimulating anti-cancer immunity and tumor regression (). Nevertheless, the amount of HSP90α in patient serum correlates with tumor progression and the presence of distant metastasis (Liu et al., 2019, 2021).
eHSP90 pro-tumoral activity occurs with different mechanisms. It can activate extracellular clients, promoting the formation of a favorable milieu for cell migration or it can bind to surface receptors stimulating cell survival, movement and aggressiveness (Li et al., 2013).
eHSP90 clients include several proteins involved in extracellular matrix remodeling, like metalloproteinases (MMP2 and MMP9) (Song et al., 2010; Stellas et al., 2010; Sims et al., 2011; ), the pro-form of tissue plasminogen activator (tPA) (McCready et al., 2010), the lysil oxidase-like protein 2 (LOXL2), and fibronectin (; ). This suggests that eHSP90 has the potential to regulate matrix deposition and stiffness, thus influencing cancer aggressiveness (; ; Wong and Jay, 2016).
eHSP90 binds to several cell surface receptors and triggers signal transduction pathways that contribute to malignancy. It interacts with Toll-like receptor 4 (TLR4) and signals via Proto-oncogene tyrosine-protein kinase (SRC) to focal adhesion kinase (FAK), which is critical for cell motility. eHSP90-mediated TLR4 activation may also induce the transactivation of the epithelial growth factor receptor (EGFR), further contributing to malignancy (Thuringer et al., 2011). Binding to the extracellular domain of HER2, eHSP90 unleashes SRC, ERK, and RAC-alpha serine/threonine-protein kinase (AKT) pathways (; Sidera et al., 2008). eHSP90 also interacts with low-density lipoprotein receptor-related protein 1 (LRP1). LRP1 is a ubiquitous endocytic receptor that recognizes several ligands and transduces signals, regulating tissue remodeling, cell survival and inflammatory reactions (). eHSP90 binding to LRP1 activates ERK, AKT, and NF-κB pathways and induces ephrin type-A receptor 2 (EPHA2) recruitment and activation, promoting lamellipodia formation and cancer cell motility and invasion (; ; Tsen et al., 2013; Nagaraju et al., 2015).
Interestingly, a small eHSP90α-specific fragment, located at the boundary between the linker and the M domain, is sufficient to reproduce the ability of the entire chaperone to induce cell migration trough LRP1 (; Zou et al., 2017). Nevertheless, increasing evidence indicates that eHSP90 pro-tumorigenic activity is regulated and directed by secreted co-chaperones (Table 1). This suggests that co-chaperones may regulate the accessibility of the HSP90 pro-motility fragment, besides conferring specificity to clients and receptors.
TABLE 1
| Co-chaperone | Intracellular functions | Role of eHSP90 complexes in cancer progression | References |
| CDC37 | Stabilization of HSP90 open conformation; presentation of kinases clients to HSP90 | Induction of cancer cell migration through HER2 and EGF receptors | ; |
| AHA1 | Induction of HSP90 ATPase activity | Competition with TIMP2 for the activation of the HSP90-MMP2 complex | |
| p23 | Stabilization of HSP90 closed 2 state | MMP2 activation | Sims et al., 2011 |
| HOP | Stabilization of HSP90 open conformation; transfer of client proteins from HSP70 to HSP90 | MMP2 activation | Sims et al., 2011; ; |
| HIP | Transfer of client proteins from HSP70 to HSP90 | Not investigated | |
| HSP40 | Stimulation of the association between HSP70 and HIP; transfer of client proteins from HSP70 to HSP90 | MMP2 activation | ; Sims et al., 2011 |
| HSP70 | ATP-dependent molecular chaperone; binding and transfer of client proteins to HSP90 | MMP2 activation; TLR4 Activation | ; Sims et al., 2011; ; |
| PP5 | HSP90 phosphatase | Not investigated | |
| FKBP51/FKBP52 | Peptidyl-prolyl-isomerase involved in client protein maturation | Not investigated | |
| Morgana | Form a complex with ADP-bound HSP90; regulation of intracellular signaling pathways | Induction of cancer cell migration through TLR4, TLR2, and LRP1 receptors | Seclì et al., 2021 |
| Clusterin | Mediation of intracellular proteostasis | Induction of cancer cell migration through LRP1 receptor | Tian et al., 2019 |
Roles of extracellular HSP90 co-chaperones.
eHSP90 Complexes Remodel Tumor Microenvironment
Four co-chaperones, namely HSP70, HSP40, HOP, and p23 were found in complex with eHSP90α in breast cancer cell conditioned medium. These factors increase eHSP90α binding to MMP2, enhancing MMP2 activation and resulting in cancer cell invasion (Figure 1B). HSP70 depletion from conditioned media or its pharmacological inhibition impairs eHSP90-mediated MMP2 activation (Sims et al., 2011). Similar multichaperone complexes have been found also in other contexts. eHSP90α and eHSP70 released on the surface of extracellular vesicles are responsible for tumor-induced muscle wasting. Both HSP70 and HSP90α are required to activate TLR4 on muscle cells to induce cachexia (Zhang et al., 2017), however it is not clear if a direct interaction occurs. Experiments in neuroblasts demonstrate that eHOP, eHSP70, and eHSP90 cooperate to influence cell migration, suggesting the possibility that these chaperones generate a functional complex (Miyakoshi et al., 2017). In these studies, the presence of further components has not been investigated.
In fibrosarcoma cell conditioned medium, eHSP90α requires an articulated competing system between co-chaperones to induce client maturation (). Researchers identified the Tissue inhibitor of metalloproteinase 2 (TIMP2), an endogenous inhibitor of MMPs, as a new extracellular co-chaperone of eHSP90α. TIMP2 forms a complex with eHSP90α, PP5 and HOP and inhibits eHSP90α ATPase activity by binding its middle domain. In this context, TIMP2 functions as a scaffolding co-chaperone that loads MMP2 to eHSP90α, keeping MMP2 in a transiently inhibited state. AHA1 competes with TIMP2 for the binding to the HSP90α-MMP2 complex (Figure 1B). Indeed, TIMP2, and AHA1 occupy the same epitope on the M-domain of eHSP90α and AHA1 may displace TIMP2 from the HSP90α-MMP2 complex, promoting the full activation of the metalloproteinase and inducing matrix degradation. The evidence for sequential events influencing eHSP90 complex composition and client activation suggests the existence of bona fide eHSP90 machineries. It remains a matter of debate if HSP90 extracellular functions are dependent on its ATPase activity. Many studies have proposed and demonstrated that eHSP90 can chaperone clients in an ATP independent manner (; Sims et al., 2011; McCready et al., 2014), however proved that eHSP90 needs ATP hydrolysis to properly fold MMP2. Since cells can actively secrete ATP in response to a variety of stressful stimuli (), it is possible that, at least in some contexts, eHSP90 binds, and hydrolases ATP to carry out its extracellular duties.
eHSP90 Complexes Activate Cancer Cell Surface Receptors
Several co-chaperones assist and regulate eHSP90 binding to cell surface receptors, likely conferring binding specificity and/or promoting specific signaling events.
CDC37 has been found secreted by triple negative breast cancer cells and localized on the cell surface (). Similarly to its intracellular counterpart, eCDC37 acts as a co-factor of eHSP90. The HSP90 isoform involved in this specific complex has not been investigated. The eHSP90/eCDC37 complex interacts on the cell surface with HER2 and EGF receptors allowing breast cancer cell migration (Figure 1C). Indeed, treatment with anti-CDC37 antibodies impairs cancer cell migration and in vivo administration of an HSP90 blocking antibody, able to disrupt the HSP90-CDC37 complex, inhibits metastasis formation (Stellas et al., 2007, 2010; ).
Clusterin is a secreted glycoprotein that functions as an ATP-independent extracellular chaperone for several clients in extracellular fluids, acting by inhibiting amorphous protein aggregation and contributing to the clearance of unfolded proteins (; ; Wyatt et al., 2011). LDL Receptor Related Protein 2 (LRP2) and Plexin A4 have been identified as Clusterin receptors in brain (, ). It has been demonstrated that Clusterin interacts with eHSP90α and increases its ability to associate with LRP1. The Clusterin/HSP90α complex binds to LRP1 with higher affinity in respect to eHP90α alone and potentiates the signal, increasing breast cancer cell migration (Figure 1C). Clusterin and eHSP90α synergistic signaling induces E-cadherin downregulation and increases the expression of N-cadherin, Snail, Slug, and Zeb1, promoting epithelial to mesenchymal transition. In vivo co-administration of eHSP90α and Clusterin in mice carrying breast cancer cells derived tumors significantly increases metastasis (Tian et al., 2019).
Morgana is a HSP90 co-chaperone coded by the CHORDC1 gene. Inside the cells, Morgana regulates signal transduction by binding and inhibiting Rho kinases I and II (; ) and promotes NF-kB activation (). It is also involved in microtubule polymerization (Palumbo et al., 2020), EGF receptor trafficking (), and extracellular vesicle secretion (Urabe et al., 2020). We recently found that Morgana is secreted by several cancer cells through an unconventional pathway and it associates with HSP90 in the extracellular milieu. The involvement of a specific HSP90 isoform has not been yet clarified. Cancer cells downregulated for Morgana migrate less than control cells and the addition of a recombinant Morgana in the medium totally rescues the defect in cell migration. HSP90 blocking antibodies revert this ability, suggesting that the eMorgana works in concert with HSP90 to promote cell migration. We found that TLR4, TLR2, and LRP1 are all required for eMorgana function (Figure 1C). Indeed, the impairment of the activity of these receptors by blocking antibodies or RNA interference makes the cells insensitive to Morgana pro-migratory signals. The available data indicate that Morgana binds directly to TLR2, while it requires additional components, present in the cancer cell conditioned medium, to bind to LRP1. The interaction between Morgana and TLR4 remains elusive and the possibility that TLR4 may participate to Morgana signal transduction thank to a cross-talk with TLR2 and LRP1 has to be taken into account. The fact that cancer cell migration in presence of Morgana blocking antibodies is not further repressed by inhibiting HSP90 suggests that the extracellular complex containing HSP90 and Morgana is the main responsible for migration, at least in a subgroup of cancer cells (Seclì et al., 2021).
eHSP90 Complexes as Therapeutic Targets
Eighteen HSP90 inhibitors have entered clinical trials but none has been approved by the FDA, mainly due to associated toxicity (Xiao and Liu, 2020). Several pre-clinical trials are now exploring the possibility to selectively inhibit the extracellular HSP90 (Tsutsumi et al., 2008; Wang et al., 2009; Song et al., 2010). However, since eHSP90 may also induce anti-cancer immunity (), the opportunity to specifically target eHSP90 pro-tumorigenic complexes would further improve the therapeutic value of these approaches. This strategy is achievable by targeting co-chaperones present in pro-tumorigenic complexes (; ; ). In vitro and in vivo experiments have proved that targeting extracellular co-chaperones have the potential to inhibit cancer progression. Treatments with antibodies against AHA1 or TIMP2 are able to inhibit MMP2 activity (). The use of cell impermeable anti-CDC37 antibody compromises the invasiveness of breast cancer tumor cells (). Similar effects have been described in vitro and in cancer preclinical models for the monoclonal antibody against eHSP90 (4C5), able to disrupt the eCDC37/eHSP90/HER2 or EGFR complex (Stellas et al., 2007, 2010; ). A monoclonal antibody against Morgana (mAb 5B11B3) has been recently identified as an inhibitor of cancer cell migration both in vitro and in pre-clinical models. mAb 5B11B3 systemic treatment in immunocompromised tumor-bearing mice inhibits cancer cell intravasation and metastasis. In syngeneic cancer mouse models, in addition to reducing metastases, mAb 5B11B3 abates tumor growth by promoting anti-cancer immunity mediated by macrophages and CD8+ T lymphocytes (Seclì et al., 2021).
Discussion
While the role of eHSP90 as a promoter of cancer progression is well established, the involvement of its extracellular co-chaperones remains poorly investigated. Available data suggest that eHSP90 binds to extracellular co-chaperones, forms different complexes and generates machineries with specific missions in the outside. Little is known on the dynamic of eHSP90 complex formation and on their possible cooperation in activating cell surface receptors and extracellular clients. It has been demonstrated that inside cancer cells, HSP90 can form stable aberrant multi-chaperone complexes that facilitate cell survival (Rodina et al., 2016). In the extracellular medium, similar complexes could work as platforms, clustering surface receptors and regulating their transactivation, or acting as scaffolds for extracellular matrix remodeling. A deep understanding of the eHSP90 interaction network appears a promising starting point to develop new diagnostics tools and provide potential targets for drug intervention in cancer.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
All authors wrote the manuscript and approved the contents for publication.
Funding
This work was supported by the Italian Association for Cancer Research (AIRC IG24930) and by the Regione Piemonte (Digital Technology for Lung Cancer Treatment—DEFLeCT) to MB.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
Baker-WilliamsA. J.HashmiF.BudzynskiM. A.WoodfordM. R.GleicherS.HimanenS. V.et al (2019). Co-chaperones TIMP2 and AHA1 competitively regulate extracellular HSP90: client MMP2 activity and matrix proteolysis.Cell Rep.281894–1906.e96. 10.1016/j.celrep.2019.07.045
2
BarrottJ. J.HaysteadT. A. (2013). Hsp90, an unlikely ally in the war on cancer.FEBS J.2801381–1396. 10.1111/febs.12147
3
Belsches-JablonskiA. P.BiscardiJ. S.PeavyD. R.TiceD. A.RomneyD. A.ParsonsS. J. (2001). Src family kinases and HER2 interactions in human breast cancer cell growth and survival.Oncogene201465–1475. 10.1038/sj.onc.1204205
4
BhatiaA.O’BrienK.ChenM.WoodleyD. T.LiW. (2016). Keratinocyte-secreted heat shock protein-90alpha: leading wound reepithelialization and closure.Adv. Wound Care5176–184. 10.1089/wound.2014.0620
5
BoelN. M.HunterM. C.EdkinsA. L. (2018). LRP1 is required for novobiocin-mediated fibronectin turnover.Sci. Rep.8:11438. 10.1038/s41598-018-29531-2
6
BohonowychJ. E.HanceM. W.NolanK. D.DefeeM.ParsonsC. H.IsaacsJ. S. (2014). Extracellular Hsp90 mediates an NF-kappaB dependent inflammatory stromal program: implications for the prostate tumor microenvironment.Prostate74395–407. 10.1002/pros.22761
7
BuffartT. E.CarvalhoB.van GriekenN. C.van WieringenW. N.TijssenM.KranenbargE. M.et al (2012). Losses of chromosome 5q and 14q are associated with favorable clinical outcome of patients with gastric cancer.Oncologist17653–662. 10.1634/theoncologist.2010-0379
8
CalderwoodS. K. (2018). Heat shock proteins and cancer: intracellular chaperones or extracellular signalling ligands?Philos. Trans. R. Soc. Lond. B Biol. Sci.373:20160524. 10.1098/rstb.2016.0524
9
CalderwoodS. K.GongJ.MurshidA. (2016). Extracellular HSPs: the complicated roles of extracellular HSPs in immunity.Front. Immunol.7:159. 10.3389/fimmu.2016.00159
10
CaleroM.TokudaT.RostagnoA.KumarA.ZlokovicB.FrangioneB.et al (1999). Functional and structural properties of lipid-associated apolipoprotein J (clusterin).Biochem. J.344(Pt 2), 375–383.
11
ChakrabortyA.BoelN. M.EdkinsA. L. (2020). HSP90 interacts with the fibronectin N-terminal domains and increases matrix formation.Cells9:272. 10.3390/cells9020272
12
ChenJ. S.HsuY. M.ChenC. C.ChenL. L.LeeC. C.HuangT. S. (2010). Secreted heat shock protein 90alpha induces colorectal cancer cell invasion through CD91/LRP-1 and NF-kappaB-mediated integrin alphaV expression.J. Biol. Chem.28525458–25466. 10.1074/jbc.M110.139345
13
ChengC. F.SahuD.TsenF.ZhaoZ.FanJ.KimR.et al (2011). A fragment of secreted HSP90alpha carries properties that enable it to accelerate effectively both acute and diabetic wound healing in mice.J. Clin. Invest.1214348–4361. 10.1172/JCI46475
14
ChengQ.ChangJ. T.GeradtsJ.NeckersL. M.HaysteadT.SpectorN. L.et al (2012). Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer.Breast Cancer Res.14:R62. 10.1186/bcr3168
15
CrescitelliR.LasserC.JangS. C.CvjetkovicA.MalmhallC.KarimiN.et al (2020). Subpopulations of extracellular vesicles from human metastatic melanoma tissue identified by quantitative proteomics after optimized isolation.J. Extracell. Vesicles9:1722433. 10.1080/20013078.2020.1722433
16
Criado-MarreroM.ReinT.BinderE. B.PorterJ. T.KorenJ.IIIBlairL. J. (2018). Hsp90 and FKBP51: complex regulators of psychiatric diseases.Philos. Trans. R. Soc. Lond. B Biol. Sci.373:20160532. 10.1098/rstb.2016.0532
17
D’AnnessaI.HurwitzN.PirotaV.BerettaG. L.TinelliS.WoodfordM.et al (2020). Design of disruptors of the Hsp90-Cdc37 interface.Molecules25:360. 10.3390/molecules25020360
18
De MaioA. (2014). Extracellular Hsp70: export and function.Curr. Protein Pept. Sci.15225–231. 10.2174/1389203715666140331113057
19
De MaioA.VazquezD. (2013). Extracellular heat shock proteins: a new location, a new function.Shock40239–246. 10.1097/SHK.0b013e3182a185ab
20
Di VirgilioF. (2021). P2X7 is a cytotoxic receptor.maybe not: implications for cancer.Purinergic Signal.1755–61. 10.1007/s11302-020-09735-w
21
DongH.ZouM.BhatiaA.JayaprakashP.HofmanF.YingQ.et al (2016). Breast cancer MDA-MB-231 cells use secreted heat shock protein-90alpha (HSP90alpha) to survive a hostile hypoxic environment.Sci. Rep.6:20605. 10.1038/srep20605
22
EdkinsA. L.PriceJ. T.PockleyA. G.BlatchG. L. (2018). Heat shock proteins as modulators and therapeutic targets of chronic disease: an integrated perspective.Philos. Trans. R. Soc. Lond. B Biol. Sci.373:20160521. 10.1098/rstb.2016.0521
23
El HamidiehA.GrammatikakisN.PatsavoudiE. (2012). Cell surface Cdc37 participates in extracellular HSP90 mediated cancer cell invasion.PLoS One7:e42722. 10.1371/journal.pone.0042722
24
FerrettiR.PalumboV.Di SavinoA.VelascoS.SbroggioM.SportolettiP.et al (2010). Morgana/chp-1, a ROCK inhibitor involved in centrosome duplication and tumorigenesis.Dev. Cell18486–495. 10.1016/j.devcel.2009.12.020
25
FerrettiR.SbroggioM.Di SavinoA.FusellaF.BerteroA.MichowskiW.et al (2011). Morgana and melusin: two fairies chaperoning signal transduction.Cell Cycle103678–3683. 10.4161/cc.10.21.18202
26
FusellaF.FerrettiR.RecuperoD.RoccaS.Di SavinoA.TornilloG.et al (2014). Morgana acts as a proto-oncogene through inhibition of a ROCK-PTEN pathway.J. Pathol.234152–163. 10.1002/path.4341
27
FusellaF.SecliL.BussoE.KrepelovaA.MoisoE.RoccaS.et al (2017). The IKK/NF-kappaB signaling pathway requires Morgana to drive breast cancer metastasis.Nat. Commun.8:1636. 10.1038/s41467-017-01829-1
28
Gallegos RuizM. I.FloorK.RoepmanP.RodriguezJ. A.MeijerG. A.MooiW. J.et al (2008). Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target.PLoS One3:e0001722. 10.1371/journal.pone.0001722
29
GanoJ. J.SimonJ. A. (2010). A proteomic investigation of ligand-dependent HSP90 complexes reveals CHORDC1 as a novel ADP-dependent HSP90-interacting protein.Mol. Cell. Proteomics9255–270. 10.1074/mcp.M900261-MCP200
30
GehrmannM.MarienhagenJ.Eichholtz-WirthH.FritzE.EllwartJ.JaattelaM.et al (2005). Dual function of membrane-bound heat shock protein 70 (Hsp70), Bag-4, and Hsp40: protection against radiation-induced effects and target structure for natural killer cells.Cell Death Differ.1238–51. 10.1038/sj.cdd.4401510
31
GopalU.BohonowychJ. E.Lema-TomeC.LiuA.Garrett-MayerE.WangB.et al (2011). A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion.PLoS One6:e17649. 10.1371/journal.pone.0017649
32
GuzhovaI. V.ShevtsovM. A.AbkinS. V.PankratovaK. M.MargulisB. A. (2013). Intracellular and extracellular Hsp70 chaperone as a target for cancer therapy.Int. J. Hyperthermia29399–408. 10.3109/02656736.2013.807439
33
HaagA.WalserM.HenggelerA.HajnalA. (2020). The CHORD protein CHP-1 regulates EGF receptor trafficking and signaling in C. elegans and in human cells.Elife9:e50986. 10.7554/eLife.50986
34
HajjG. N.ArantesC. P.DiasM. V.RoffeM.Costa-SilvaB.LopesM. H.et al (2013). The unconventional secretion of stress-inducible protein 1 by a heterogeneous population of extracellular vesicles.Cell. Mol. Life Sci.703211–3227. 10.1007/s00018-013-1328-y
35
HouQ.ChenS.AnQ.LiB.FuY.LuoY. (2021). Extracellular HSP90alpha promotes tumor lymphangiogenesis and lymph node metastasis in breast cancer.Int. J. Mol. Sci.22:7747. 10.3390/ijms22147747
36
JaegerA. M.WhitesellL. (2019). HSP90: enabler of cancer adaptation.Ann. Rev. Cancer Biol.3275–297. 10.1146/annurev-cancerbio-030518-055533
37
JenneD. E.TschoppJ. (1989). Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid.Proc. Natl. Acad. Sci. U.S.A.867123–7127. 10.1073/pnas.86.18.7123
38
KaiF.LaklaiH.WeaverV. M. (2016). Force matters: biomechanical regulation of cell invasion and migration in disease.Trends Cell Biol.26486–497. 10.1016/j.tcb.2016.03.007
39
KangB. H.ShimY. J.TaeY. K.SongJ. A.ChoiB. K.ParkI. S.et al (2014). Clusterin stimulates the chemotactic migration of macrophages through a pertussis toxin sensitive G-protein-coupled receptor and Gbetagamma-dependent pathways.Biochem. Biophys. Res. Commun.445645–650. 10.1016/j.bbrc.2014.02.071
40
KangS. S.KurtiA.WojtasA.BakerK. E.LiuC. C.KanekiyoT.et al (2016). Identification of plexin A4 as a novel clusterin receptor links two Alzheimer’s disease risk genes.Hum. Mol. Genet.253467–3475. 10.1093/hmg/ddw188
41
KimJ.GeeH. Y.LeeM. G. (2018). Unconventional protein secretion new insights into the pathogenesis and therapeutic targets of human diseases.J. Cell Sci.131:jcs213686. 10.1242/jcs.213686
42
LeeK. J.KimY. M.KimD. Y.JeoungD.HanK.LeeS. T.et al (2006). Release of heat shock protein 70 (Hsp70) and the effects of extracellular Hsp70 on matric metalloproteinase-9 expression in human monocytic U937 cells.Exp. Mol. Med.38364–374. 10.1038/emm.2006.43
43
LiJ.SorokaJ.BuchnerJ. (2012). The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones.Biochim. Biophys. Acta1823624–635. 10.1016/j.bbamcr.2011.09.003
44
LiW.LiY.GuanS.FanJ.ChengC. F.BrightA. M.et al (2007). Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing.EMBO J.261221–1233. 10.1038/sj.emboj.7601579
45
LiW.TsenF.SahuD.BhatiaA.ChenM.MulthoffG.et al (2013). Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally.Int. Rev. Cell Mol. Biol.303203–235. 10.1016/B978-0-12-407697-6.00005-2
46
LiaoD. F.JinZ. G.BaasA. S.DaumG.GygiS. P.AebersoldR.et al (2000). Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells.J. Biol. Chem.275189–196. 10.1074/jbc.275.1.189
47
LiuH.ZhangZ.HuangY.WeiW.NingS.LiJ.et al (2021). Plasma HSP90AA1 predicts the risk of breast cancer onset and distant metastasis.Front. Cell Dev. Biol.9:639596. 10.3389/fcell.2021.639596
48
LiuW.LiJ.ZhangP.HouQ.FengS.LiuL.et al (2019). A novel pan-cancer biomarker plasma heat shock protein 90alpha and its diagnosis determinants in clinic.Cancer Sci.1102941–2959. 10.1111/cas.14143
49
McCreadyJ.SimsJ. D.ChanD.JayD. G. (2010). Secretion of extracellular HSP90alpha via exosomes increases cancer cell motility: a role for plasminogen activation.BMC Cancer10:294. 10.1186/1471-2407-10-294
50
McCreadyJ.WongD. S.BurlisonJ. A.YingW.JayD. G. (2014). An impermeant ganetespib analog inhibits extracellular Hsp90-mediated cancer cell migration that involves Lysyl oxidase 2-like protein.Cancers61031–1046. 10.3390/cancers6021031
51
MichowskiW.FerrettiR.WisniewskaM. B.AmbrozkiewiczM.BeresewiczM.FusellaF.et al (2010). Morgana/CHP-1 is a novel chaperone able to protect cells from stress.Biochim. Biophys. Acta18031043–1049. 10.1016/j.bbamcr.2010.05.005
52
MiyakoshiL. M.Marques-CoelhoD.De SouzaL. E. R.LimaF. R. S.MartinsV. R.ZanataS. M.et al (2017). Evidence of a cell surface role for Hsp90 complex proteins mediating neuroblast migration in the subventricular zone.Front. Cell. Neurosci.11:138. 10.3389/fncel.2017.00138
53
NagarajuG. P.LongT. E.ParkW.LandryJ. C.Taliaferro-SmithL.FarrisA. B.et al (2015). Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer.Mol. Carcinog.541147–1158. 10.1002/mc.22185
54
NanbuK.KonishiI.MandaiM.KurodaH.HamidA. A.KomatsuT.et al (1998). Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas.Cancer Detect. Prev.22549–555. 10.1046/j.1525-1500.1998.00069.x
55
PalumboV.TariqA.BorgalL.MetzJ.BrancaccioM.GattiM.et al (2020). Drosophila morgana is an Hsp90-interacting protein with a direct role in microtubule polymerisation.J. Cell Sci.133:jcs236786. 10.1242/jcs.236786
56
RodinaA.WangT.YanP.GomesE. D.DunphyM. P.PillarsettyN.et al (2016). The epichaperome is an integrated chaperome network that facilitates tumour survival.Nature538397–401. 10.1038/nature19807
57
RohlA.RohrbergJ.BuchnerJ. (2013). The chaperone Hsp90: changing partners for demanding clients.Trends Biochem. Sci.38253–262. 10.1016/j.tibs.2013.02.003
58
SahuD.ZhaoZ.TsenF.ChengC. F.ParkR.SituA. J.et al (2012). A potentially common peptide target in secreted heat shock protein-90alpha for hypoxia-inducible factor-1alpha-positive tumors.Mol. Biol. Cell23602–613. 10.1091/mbc.E11-06-0575
59
SantosT. G.MartinsV. R.HajjG. N. M. (2017). Unconventional secretion of heat shock proteins in cancer.Int. J. Mol. Sci.18:946. 10.3390/ijms18050946
60
SchopfF. H.BieblM. M.BuchnerJ. (2017). The HSP90 chaperone machinery.Nat. Rev. Mol. Cell Biol.18345–360. 10.1038/nrm.2017.20
61
SeclìL.AvalleL.PoggioP.FragaleG.CannataC.ContiL.et al (2021). Targeting the extracellular HSP90 co-chaperone Morgana inhibits cancer cell migration and promotes anti-cancer immunity.Cancer Res.814794–4807. 10.1158/0008-5472.can-20-3150
62
SecliL.FusellaF.AvalleL.BrancaccioM. (2021). The dark-side of the outside: how extracellular heat shock proteins promote cancer.Cell. Mol. Life Sci.784069–4083. 10.1007/s00018-021-03764-3
63
ShevtsovM.BalogiZ.KhachatryanW.GaoH.VighL.MulthoffG. (2020). Membrane-associated heat shock proteins in oncology: from basic research to new theranostic targets.Cells9:1263. 10.3390/cells9051263
64
SideraK.PatsavoudiE. (2008). Extracellular HSP90: conquering the cell surface.Cell Cycle71564–1568. 10.4161/cc.7.11.6054
65
SideraK.GaitanouM.StellasD.MatsasR.PatsavoudiE. (2008). A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2.J. Biol. Chem.2832031–2041. 10.1074/jbc.M701803200
66
SideraK.SamiotakiM.YfantiE.PanayotouG.PatsavoudiE. (2004). Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system.J. Biol. Chem.27945379–45388. 10.1074/jbc.M405486200
67
SiligardiG.PanaretouB.MeyerP.SinghS.WoolfsonD. N.PiperP. W.et al (2002). Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37.J. Biol. Chem.27720151–20159. 10.1074/jbc.M201287200
68
SimsJ. D.McCreadyJ.JayD. G. (2011). Extracellular heat shock protein (Hsp)70 and HSP90alpha assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion.PLoS One6:e18848. 10.1371/journal.pone.0018848
69
SongX.WangX.ZhuoW.ShiH.FengD.SunY.et al (2010). The regulatory mechanism of extracellular Hsp90{alpha} on matrix metalloproteinase-2 processing and tumor angiogenesis.J. Biol. Chem.28540039–40049. 10.1074/jbc.M110.181941
70
SorgeM.BrancaccioM. (2016). Melusin promotes a protective signal transduction cascade in stressed hearts.Front. Mol. Biosci.3:53. 10.3389/fmolb.2016.00053
71
SreedharA. S.KalmarE.CsermelyP.ShenY. F. (2004). Hsp90 isoforms: functions, expression and clinical importance.FEBS Lett.56211–15. 10.1016/s0014-5793(04)00229-7
72
StellasD.El HamidiehA.PatsavoudiE. (2010). Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits.BMC Cell Biol.11:51. 10.1186/1471-2121-11-51
73
StellasD.KaramerisA.PatsavoudiE. (2007). Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis.Clin. Cancer Res.131831–1838. 10.1158/1078-0432.CCR-06-1585
74
TaipaleM.KrykbaevaI.KoevaM.KayatekinC.WestoverK. D.KarrasG. I.et al (2012). Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.Cell150987–1001. 10.1016/j.cell.2012.06.047
75
TangX.ChangC.GuoJ.LincolnV.LiangC.ChenM.et al (2019). Tumour-secreted HSP90alpha on external surface of exosomes mediates tumour stromal cell communication via autocrine and paracrine mechanisms.Sci. Rep.9:15108. 10.1038/s41598-019-51704-w
76
ThuringerD.HammannA.BenikhlefN.FourmauxE.BouchotA.WettsteinG.et al (2011). Transactivation of the epidermal growth factor receptor by heat shock protein 90 via Toll-like receptor 4 contributes to the migration of glioblastoma cells.J. Biol. Chem.2863418–3428. 10.1074/jbc.M110.154823
77
TianY.WangC.ChenS.LiuJ.FuY.LuoY. (2019). Extracellular HSP90alpha and clusterin synergistically promote breast cancer epithelial-to-mesenchymal transition and metastasis via LRP1.J. Cell Sci.132:jcs228213. 10.1242/jcs.228213
78
TsenF.BhatiaA.O’BrienK.ChengC. F.ChenM.HayN.et al (2013). Extracellular heat shock protein 90 signals through subdomain II and the NPVY motif of LRP-1 receptor to Akt1 and Akt2: a circuit essential for promoting skin cell migration in vitro and wound healing in vivo.Mol. Cell. Biol.334947–4959. 10.1128/MCB.00559-13
79
TsutsumiS.ScrogginsB.KogaF.LeeM. J.TrepelJ.FeltsS.et al (2008). A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion.Oncogene272478–2487. 10.1038/sj.onc.1210897
80
UllrichS. J.MooreS. K.AppellaE. (1989). Transcriptional and translational analysis of the murine 84- and 86-kDa heat shock proteins.J. Biol. Chem.2646810–6816.
81
UrabeF.KosakaN.SawaY.YamamotoY.ItoK.YamamotoT.et al (2020). miR-26a regulates extracellular vesicle secretion from prostate cancer cells via targeting SHC4, PFDN4, and CHORDC1.Sci. Adv.6:eaay3051. 10.1126/sciadv.aay3051
82
VelichkoA. K.MarkovaE. N.PetrovaN. V.RazinS. V.KantidzeO. L. (2013). Mechanisms of heat shock response in mammals.Cell. Mol. Life Sci.704229–4241. 10.1007/s00018-013-1348-7
83
WangX.SongX.ZhuoW.FuY.ShiH.LiangY.et al (2009). The regulatory mechanism of HSP90alpha secretion and its function in tumor malignancy.Proc. Natl. Acad. Sci. U.S.A.10621288–21293. 10.1073/pnas.0908151106
84
WongD. S.JayD. G. (2016). Emerging roles of extracellular Hsp90 in cancer.Adv. Cancer Res.129141–163. 10.1016/bs.acr.2016.01.001
85
WyattA. R.YerburyJ. J.BerghoferP.GreguricI.KatsifisA.DobsonC. M.et al (2011). Clusterin facilitates in vivo clearance of extracellular misfolded proteins.Cell. Mol. Life Sci.683919–3931. 10.1007/s00018-011-0684-8)10.1007/s00018-011-0684-8
86
XiaoY.LiuY. (2020). Recent advances in the discovery of novel HSP90 inhibitors: an update from 2014.Curr. Drug Targets21302–317. 10.2174/1389450120666190829162544
87
ZhangG.LiuZ.DingH.ZhouY.DoanH. A.SinK. W. T.et al (2017). Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90.Nat. Commun.8:589. 10.1038/s41467-017-00726-x
88
ZouM.BhatiaA.DongH.JayaprakashP.GuoJ.SahuD.et al (2017). Evolutionarily conserved dual lysine motif determines the non-chaperone function of secreted HSP90alpha in tumour progression.Oncogene362160–2171. 10.1038/onc.2016.375
89
ZuehlkeA. D.BeebeK.NeckersL.PrinceT. (2015). Regulation and function of the human HSP90AA1 gene.Gene5708–16. 10.1016/j.gene.2015.06.018
Summary
Keywords
eHSP90 (Extracellular Heat Shock Protein 90), tumor microenvironment, CDC37, Clusterin, CHORDC1, Morgana, LRP1, TLR (toll like receptors)
Citation
Poggio P, Sorge M, Seclì L and Brancaccio M (2021) Extracellular HSP90 Machineries Build Tumor Microenvironment and Boost Cancer Progression. Front. Cell Dev. Biol. 9:735529. doi: 10.3389/fcell.2021.735529
Received
02 July 2021
Accepted
20 September 2021
Published
14 October 2021
Volume
9 - 2021
Edited by
Suhasini Joshi, Memorial Sloan Kettering Cancer Center, United States
Reviewed by
Valeria De Pasquale, University of Naples Federico II, Italy; Francesca Di Sole, Des Moines University, United States; Garima Kaushik, Champions Oncology, Inc., United States
Updates
Copyright
© 2021 Poggio, Sorge, Seclì and Brancaccio.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mara Brancaccio, mara.brancaccio@unito.it
This article was submitted to Cellular Biochemistry, a section of the journal Frontiers in Cell and Developmental Biology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.